Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) is a clinical-stage biopharmaceutical company developing small molecule and antibody-based drug candidates for obesity and oncology. The company generates no product revenue and funds operations through equity and debt financing, as it has no approved or commercialized products as of the 10-K filed March 9, 2026. Its lead obesity candidate, CRB-913, is a peripherally restricted oral CB1 receptor inverse agonist that completed a Phase 1a SAD/MAD study in December 2025 with no serious treatment-emergent adverse events reported, and entered the Phase 1b CANYON-1 dose-range finding study in December 2025. Its oncology pipeline includes CRB-701, a Nectin-4-targeting antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical in February 2023 for the U.S., Canada, EU, UK, and Australia, currently in Phase 1/2 trials for advanced solid tumors. CRB-601, an anti-αvβ8 integrin monoclonal antibody for solid tumors, was formerly in the pipeline. The company was incorporated in Delaware and has operated as a pre-revenue clinical-stage entity through FY2025.

Revenue model

No product revenue. Operations are financed through equity issuances and debt, including a loan and security agreement with K2 HealthVentures LLC dated July 28, 2020. The company holds licenses, conducts clinical trials, and relies on external capital to fund R&D spending.

Products and services

CRB-913: oral peripherally restricted CB1 receptor inverse agonist for obesity; Phase 1b CANYON-1 study initiated December 2025, enrolling 240 U.S. subjects across four arms over 12 weeks. CRB-701 (SYS6002): Nectin-4-targeting ADC with MMAE payload for advanced solid tumors; Phase 1/2 Western study ongoing in U.S. and Europe; FDA fast track designation received for metastatic cervical cancer (December 2024) and HNSCC (September 2025). CRB-601: anti-αvβ8 integrin monoclonal antibody for solid tumors; formerly in pipeline.

Customers and end markets

No commercial customers as of FY2025. End markets are obesity treatment and oncology (solid tumors including cervical cancer and head and neck squamous cell carcinoma). Clinical trial participants are enrolled in the U.S. and Europe.

Value-chain role

Clinical-stage drug developer. Licenses drug candidates from third parties (CRB-701 licensed from CSPC Megalith Biopharmaceutical), conducts clinical trials through contract research organizations, and outsources manufacturing. Does not manufacture or commercialize products.

Geographic exposure

Clinical trials conducted in the United States and Europe. CRB-701 licensed rights cover the U.S., Canada, European Union (including European Free Trade Area), United Kingdom, and Australia. CSPC conducts a separate Phase 3 China study for CRB-701 independently.

Source: SEC 10-K, filed 2026-03-09

Industry: Pharmaceutical Preparations Peers: Soligenix Inc Viskase Holdings Inc Aceragen, Inc. Immix Biopharma Inc Monopar Therapeutics Inc ONCOSEC MEDICAL Inc THERALINK TECHNOLOGIES, INC. Vaccinex Inc